# Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019)

> **NCT03983031** · PHASE1 · COMPLETED · sponsor: **Region Örebro County** · enrollment: 11 (actual)

## Conditions studied

- Obsessive-Compulsive Disorder
- Treatment Resistant Disorders

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03983031
- **Lead sponsor:** Region Örebro County
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-08
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-03-31
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2022-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03983031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03983031, "Rituximab for Obsessive-compulsive Disorder. (RITS-PO-2019)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03983031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*